Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?

被引：0
|
作者：
Barakat, Amr F. [1 ]
Mahmoud, Ahmed N. [2 ]
Elgendy, Islam Y. [2 ]
机构：
[1] Cleveland Clin Fdn, Dept Med, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2017年 / 239卷
关键词：
CONTROLLED RANDOMIZED-TRIALS; CARDIOVASCULAR SAFETY; INHIBITORS;
D O I：
10.1016/j.ijcard.2017.01.144
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 43 条
  • [31] Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus: Incretin-Based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol
    Lo, Margaret C.
    Lansang, M. Cecilia
    AMERICAN JOURNAL OF THERAPEUTICS, 2013, 20 (06) : 638 - 653
  • [32] Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
    Liu, Jiali
    Li, Ling
    Deng, Ke
    Xu, Chang
    Busse, Jason W.
    Vandvik, Per Olav
    Li, Sheyu
    Guyatt, Gordon H.
    Sun, Xin
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [33] Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors
    Lau, Kristy T. K.
    Wong, Carlos K. H.
    Au, Ivan C. H.
    Lau, Wallis C. Y.
    Man, Kenneth K. C.
    Chui, Celine S. L.
    Wong, Ian C. K.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (07):
  • [34] A Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus
    Batson, Sarah
    Burton, Hannah
    PLOS ONE, 2016, 11 (10):
  • [35] Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
    Cavallari, Ilaria
    Maddaloni, Ernesto
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (04)
  • [36] Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study
    Mogensen, U. M.
    Andersson, C.
    Fosbol, E. L.
    Schramm, T. K.
    Vaag, A.
    Scheller, N. M.
    Torp-Pedersen, C.
    Gislason, G.
    Kober, L.
    DIABETES OBESITY & METABOLISM, 2014, 16 (10) : 1001 - 1008
  • [37] Indications for incretin-based therapies of type 2 diabetes: An evaluation of study populations, study design and effectiveness of exenatide and DPP-4 inhibitors in clinical studies
    Bachmann, O. P.
    Kazda, C.
    Gallwitz, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2007, 2 (05) : 315 - 320
  • [38] What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?
    Rossing, Peter
    Persson, Frederik
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 290 - 297
  • [39] Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks
    Chai, Sanbao
    Yu, Shuqing
    Yang, Zhirong
    Wu, Shanshan
    Gao, Le
    Wang, Haining
    Zhang, Yuan
    Zhan, Siyan
    Ji, Linong
    Sun, Feng
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [40] Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes
    Lee, Matthew M. Y.
    Ghouri, Nazim
    McGuire, Darren K.
    Rutter, Martin K.
    Sattar, Naveed
    DIABETES CARE, 2021, 44 (05) : 1236 - 1241
12345